As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...
AB-1002 is an investigational one-time gene therapy administered directly to the heart to promote production of a modified version (I-1c) of the naturally occurring protein inhibitor-1, designed to ...
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across ...
Research presented by Dr Anna Keegan of University College London at the ELRIG meeting in Hinxton described how improved ...
It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...
CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...
At the ELRIG meeting in March 2026, Dr. Lucy Wheatley of Promega Corporation set out how highly sensitive luminescent assay ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and ...
Over 40 million people are living with HIV, with approximately one million new infections each year. A defining feature of the virus is its conical capsid consisting of around 1,200 capsid (CA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results